Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al.|The Lancet|2023Cited by 181
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvementSimona Soverini, Giovanni Martinelli, Gian Matteo Rigolin et al.|Cancer|2013Cited by 143
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosisRoberta Zanotti, Peter Valent, Massimiliano Bonifacio et al.|Leukemia|2021Cited by 55
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)Massimo Breccia, Filíppo Gherlinzoni, Francesca Palandri et al.|Cancer|2025Cited by 10
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Elena Maria Elli et al.|Cancer|2024Cited by 10